US Approvals Analysis: Abbott Leads Another Strong Month For Novel Approvals
Executive Summary
Abbott Laboratories accounted for two of five original PMA approvals recorded by US FDA in August. That update and more from Medtech Insight's Approvals Tracker.
You may also be interested in...
ACC 2018 Preview: Zoll's LifeVest, Abbott's HeartMate 3 And Amplatzer, Late-Breaking Trial Devices
New clinical data with the potential to change clinical practice will be presented at the 2018 American College of Cardiology Scientific Session and Expo in Orlando, Fla., Mar. 10-12. Among the planned late-breaking trials and featured research presentations is a study of Zoll's LifeVest wearable external cardioverter-defibrillator following a heart attack; new results from a trial of Abbott's Amplatzer PFO-closure device, and long-term data on Abbott's HeartMate 3 ventricular assist device.
Medtech's High-Earners: 2016 Executive Payouts Boosted By Bonuses, Stock Awards
A Medtech Insight analysis of the highest-earning CEOs among the top medtech companies in last year's MTI 100 company league table shows that these individuals benefited mainly from stock and options holdings, as well as very generous incentive bonuses, bestowed upon them by their boards of directors. However, a couple of CEOs, including Zimmer Biomet's David Dvorak and Cardinal Health's George Barrett, who were rewarded fiscally for taking their companies to growth have had their leadership challenged since then.
US Approvals Analysis: Cook Churns Out 510(k)s In Q3
The privately held Indiana-based device firm has accelerated its 510(k)-clearance output this year, leading all firms with 19 in the third quarter, and pulling neck-and-neck with perennial leader Medtronic for 2017. Overall, FDA remains relatively steady on 510(k) volumes and is maintaining its accelerated pace of novel-device approvals.